Patient Monitors (ICU) in California

Potrero Medical develops the Accuryn® Monitoring System, a next-generation smart catheter platform designed for early detection and prediction of acute kidney injury (AKI) in critical care settings. The system transforms a standard Foley catheter into an intelligent device that automates clinical data capture, visualizes kidney function trends, and provides real-time monitoring to enable earlier clinical interventions. The platform integrates with existing hospital workflows to reduce time clinicians spend managing data while increasing time spent with patients. Accuryn targets hospital ICU and acute care environments where AKI is prevalent, including post-sepsis monitoring and intra-abdominal compartment syndrome detection. The company focuses on predictive health capabilities that surface patterns not visible through traditional monitoring, addressing the significant clinical burden of AKI, which affects approximately 47.5% of sepsis patients and results in 300,000 annual US deaths. The system is positioned for use in adult critical care units, particularly in hospitals with high-acuity patient populations requiring intensive hemodynamic and renal function monitoring.

Sotera Wireless develops the ViSi Mobile Patient Monitoring System, a comprehensive vital signs monitoring platform designed for continuous, real-time surveillance of patients in general care, acute care, and transport settings. The system utilizes body-worn sensors to provide noninvasive, cuff-less monitoring of blood pressure, oxygen saturation (SpO2), respiration rate, pulse, electrocardiography (ECG), patient posture, and cardiac arrhythmia detection. The platform integrates machine learning algorithms trained on millions of hours of patient data to recognize early signs of patient deterioration, including sepsis and life-threatening events, while minimizing false alarms and alert fatigue. Data streams directly into electronic medical records (EMR) systems, enabling clinicians to detect critical changes between scheduled vital sign checks and respond with rapid intervention. The system is designed for ambulatory patients, those in transport, and bedside monitoring, providing continuous surveillance with enhanced clinical workflow integration. The ViSi Mobile platform emphasizes patient safety through early warning systems that address the clinical gap where dangerous deterioration can occur during intervals between conventional spot-check vital sign assessments.

Ceribell develops point-of-care EEG systems for rapid seizure detection and monitoring in critical care settings. The company's flagship product, a portable EEG platform integrated with the CLARITY® AI algorithm, enables bedside detection of seizure activity, including non-convulsive seizures, in ICUs, emergency departments, and neurology units. CLARITY® is FDA-cleared for pediatric and neonatal patients, representing the first and only FDA-cleared seizure detection algorithm for newborns preterm and up. The system delivers 95% sensitivity and 97% specificity for status epilepticus detection with 99.9% negative predictive value. Ceribell's secure cloud portal features FedRAMP High cybersecurity authorization for telemedicine consultation and remote EEG interpretation. Clinical evidence demonstrates the platform is associated with 4.1-day shorter median ICU stays and improved neurological outcomes compared to conventional EEG workflows. The company supports hospitals with ongoing in-person and virtual training. Target markets include intensive care units, emergency departments, and neurology departments in acute-care hospitals. Ceribell holds multiple FDA clearances (510(k)), CE mark certification, and has published 45+ peer-reviewed publications validating diagnostic accuracy and clinical utility in critical care populations.

PyrAmes Inc develops innovative non-invasive, continuous blood pressure monitoring solutions for patients across all age groups. The company specializes in wireless, calibration-free platforms designed to eliminate the need for invasive arterial lines and improve BP measurement accuracy in critical care settings. Product platforms include: - Boppli®: FDA 510(k)-cleared continuous non-invasive BP monitoring for neonatal and pediatric patients in NICU/PICU environments. Clinical evidence published in peer-reviewed journal Neonatology demonstrates accuracy comparable to arterial lines with superior usability and safety profile. - Bosimi®: Continuous non-invasive BP monitoring system for adult inpatient and emergency department care, enabling real-time hemodynamic assessment without invasive instrumentation. - Bosimi@Home™: Home-based platform for BP diagnostics, treatment validation, and medical management, supporting chronic disease monitoring and hypertension control in ambulatory settings. PyrAmes addresses significant clinical gaps: over 50% of NICU admissions could benefit from continuous BP monitoring but currently receive only intermittent cuff measurements or invasive arterial lines due to cost and safety concerns. In adults, hypertension affects 50% of the US population and contributes to 7.6 million deaths annually worldwide, creating demand for non-invasive continuous monitoring solutions. The company holds FDA 510(k) clearance for Boppli, FDA Breakthrough Device Designation, and recognition from the American Heart Association and National Institutes of Health (NIH RADx Tech Maternal Health Challenge). PyrAmes is a founding member of the CDC National Hypertension Control Roundtable. The technology enables early detection of hemodynamic instability in vulnerable populations including preterm infants and hypertensive adults.

Masimo Corporation is a global leader in noninvasive patient monitoring solutions, specializing in innovative pulse oximetry, vital sign monitoring, and brain function monitoring technologies. Founded on breakthrough accuracy in pulse oximetry (Masimo SET®), the company develops and manufactures continuous monitoring systems for hospitals, ICUs, operating rooms, and neonatal care settings. Core product lines include Masimo SET® Pulse Oximetry for continuous, accurate oxygen saturation measurement across all patient populations and clinical settings; SedLine® Brain Function Monitoring for depth-of-anesthesia and sedation monitoring; Masimo O3® Regional Oximetry for tissue oxygenation assessment with FDA-cleared hemoglobin parameters; and Root® Patient Monitoring and Connectivity Platform, a modular hospital automation system integrating vital signs, connectivity, and clinical workflow solutions. Masimo technologies are deployed across acute care, perioperative, emergency, neonatal, and general floor environments. The company holds over 900 patents globally and serves leading hospitals and healthcare systems in 30+ countries. Known for motion-artifact rejection and performance accuracy across diverse patient populations, Masimo's solutions address clinical needs in congenital heart disease screening, critical care monitoring, anesthesia management, and cost reduction through early patient distress detection. The company emphasizes sustainability and has strategic partnerships with major healthcare technology providers including Philips. Acquired by Danaher in February 2026.

Aulisa Medical is a Palo Alto, CA-based medical device company founded in 2012 that develops FDA-cleared, wireless wearable patient monitoring systems for continuous vital sign tracking in clinical and home environments. The company specializes in cloud-based remote monitoring solutions utilizing artificial intelligence to detect inconsistencies in vital sign data and enable early intervention for potentially adverse events. Products are designed for infants, children, and adults across multiple care settings. The Guardian Angel® product line serves as the primary offering, functioning as both a consumer baby monitor and clinical-grade vital sign monitoring device. Applications include monitoring for sleep safety, chronic respiratory diseases (COPD, sleep apnea), cardiac conditions, post-procedure recovery, and aging-in-place scenarios. The company addresses the need to reduce manual vital sign spot-checking burden for both clinicians and caregivers through automated, continuous monitoring with alert capabilities. Aulisa has achieved FDA clearance for its devices and is backed by Silicon Valley venture capital investors. The company operates both direct-to-consumer and hospital/clinical distribution channels, with products available for in-home use and institutional hospital settings.